Vaxxinity (VAXX) Stock Price

Vaxxinity Price

NASDAQ·CLOSED
0.00
​
Market closed

Vaxxinity's net margin stands at 7,520,999.0%, up from -7,173.6% several years earlier.

Vaxxinity stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vaxxinity business model & stock analysis

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 87 full-time employees. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.

Frequently asked questions about Vaxxinity

8 analysts currently rate the Vaxxinity stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Vaxxinity to generate revenue of 31.67 M USD and earnings per share of -0.41 USD.

Converted at the current exchange rate, the Vaxxinity share trades at 0.00 EUR (0.00 USD).

The Vaxxinity share (VAXX) is listed on 1 stock exchanges, including: NASDAQ (VAXX).

The expected revenue of Vaxxinity is 31.67 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Vaxxinity is -51.98 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vaxxinity is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vaxxinity stock.

The price-to-sales ratio (P/S) of Vaxxinity is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vaxxinity stock.

The Eulerpool Quality Score for Vaxxinity is 3/10.

The ISIN of Vaxxinity is US92244V1044. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Vaxxinity is VAXX. The ticker symbol is used to trade Vaxxinity shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 11, 2021
ISIN
US92244V1044
Cusip
92244V104
Market capitalization
12,678.00 USDMicro Cap
52-Week Range
PEG
0.06
P/E ratio
P/Ee 2024
—
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/Ee 2027
-0.00
P/Ee 2028
-0.00
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-0.20 %
Last updated Nov 5, 2026, 3:42 AM

Vaxxinity Peer Group

Vaxxinity Ticker

NASDAQ · VAXX

Vaxxinity FIGI

VAXX:US · BBG00ZWVMKJ9VAXX:UA · BBG012X4TK67VAXX:UC · BBG012X4TK76VAXX:UN · BBG012X4TK94VAXX:UP · BBG012X4TKB1VAXX:UQ · BBG012X4TKC0VAXX:UB · BBG012X4TKD9VAXX:UM · BBG012X4TKG6VAXX:UX · BBG012X4TKH5VAXX:UD · BBG012X4TKN8VAXX:UF · BBG012X4TKR4VAXX:VY · BBG012X4TKS3

All fundamentals and in-depth analysis of Vaxxinity

Our stock analysis for Vaxxinity stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaxxinity. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.